China Approves Oral Orforglipron for Weight Management

Company Eli Lilly Event Type NMPA approval (China) Modality Small molecule (oral nonpeptide GLP-1 receptor agonist) Asset Orforglipron calcium Target GLP-1 receptor Disease Area Obesity and overweight with weight-related comorbidity Summary China’s regulator approved Lilly’s oral nonpeptide GLP-1 receptor agonist orforglipron calcium for long-term weight…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *